Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

723
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
723
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

917
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
917
Chemical Synapses01:26

Chemical Synapses

8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

650
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
650
Muscle Contraction01:10

Muscle Contraction

6.3K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Another complement inhibitor therapy for myasthenia gravis: Is it NIMBLE enough?

Med (New York, N.Y.)·2026
Same author

Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.

Journal of translational medicine·2026
Same author

Limited adoption of thymectomy for nonthymomatous myasthenia gravis.

Journal of thoracic disease·2026
Same author

Construction of patient trajectories to model clinical trial outcomes: application to myasthenia gravis.

Frontiers in digital health·2026
Same author

Thymic health under the microscope.

Nature·2026
Same author

Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease.

Med (New York, N.Y.)·2026

Related Experiment Video

Updated: Jun 17, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

Myasthenia gravis: the future is here.

Henry J Kaminski1, Patricia Sikorski1, S Isabel Coronel1

  • 1Department of Neurology and Rehabilitation Medicine and.

The Journal of Clinical Investigation
|August 6, 2024
PubMed
Summary

Myasthenia gravis (MG) is an autoimmune disease targeting the neuromuscular junction. New treatments targeting autoantibody mechanisms offer improved therapeutic options for MG patients.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury
04:44

Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury

Published on: November 1, 2024

398

Related Experiment Videos

Last Updated: Jun 17, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury
04:44

Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury

Published on: November 1, 2024

398

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is a T-cell-dependent, antibody-mediated autoimmune disorder affecting the neuromuscular junction.
  • Patients present with variable muscle weakness, from ocular symptoms to respiratory failure.
  • Recent advancements have identified distinct MG subcategories based on autoantibodies, age, and thymic pathology.

Purpose of the Study:

  • To review current understanding of MG pathophysiology and classification.
  • To explore emerging and established therapeutic strategies for MG.
  • To provide an overview of the evolving treatment landscape for myasthenia gravis.

Main Methods:

  • Literature review focusing on MG pathophysiology, classification, and treatment.
  • Analysis of recent FDA-approved therapies targeting complement and FcRn.
  • Stratification of MG subgroups by age, autoantibody type, and thymic histology.

Main Results:

  • Delineation of MG into distinct subgroups (AChR/MuSK antibody-positive, age-based, thymoma-associated, ICI-induced).
  • Approval of novel therapeutics targeting complement and FcRn pathways.
  • Improved comprehension of autoantibody effector mechanisms driving MG.

Conclusions:

  • Understanding MG subgroups facilitates targeted therapeutic development.
  • Emerging therapies targeting FcRn and complement show promise.
  • The evolving landscape of MG treatment offers new hope for patients.